Retina Development: The Next Era of Precision Therapies Is Here

Retina development continues to be driven by converging scientific, demographic, and commercial forces. With a rapidly growing patient population, and strong investor interest, there is a push for more assets into the pipeline and reshaping expectations for trial design and market access.

Retinal disease is no longer niche. Age-related macular degeneration (AMD) alone is projected to affect roughly 288 million people globally by 2040.^1. Additionally, biomedical engineers at Duke University have used induced pluripotent stem cells (iPSCs) to grow specialized blood vessel cells critical to retinal health for the first time, as of June 2026.²

FROM CHRONIC INJECTIONS TO DURABLE CONTROL

The retina space continues to move decisively from high-frequency injections toward durable control strategies.

In parallel, gene therapy is moving from exploratory to selectively mainstream. Single administration of subretinal or intravitreal products for inherited retinal diseases has already shown that durable expression is possible. Between now and 2030, we should expect second-generation gene therapies targeting more common conditions, including wet AMD and diabetic macular disease, at least at the proof-of-concept stage³.

For clinical researchers, this evolution changes what “success” looks like. Endpoints will increasingly focus on durability rather than short-term visual gains alone. Sites that can execute long-term follow-up with low attrition, robust imaging, and patient-friendly visit structures will be in the strongest position to support these programs.

EXPANDING INDICATIONS AND COMBINATION STRATEGIES

Beyond wet AMD, geographic atrophy (GA), and diabetic macular edema (DME), retinal pipeline diversification will be a defining theme. Demographic aging and the global diabetes epidemic are expanding the pool of patients with early or subclinical retinal disease, creating room for earlier intervention strategies and combination regimens across the continuum of care.

One clear trend we are seeing is the movement upstream into earlier stages of disease such as intermediate AMD, non-proliferative diabetic retinopathy without center-involving edema, and even at-risk populations identified via advanced imaging. The implication for development teams is that inclusion criteria will broaden, and visual acuity baselines may be higher, raising the bar for detecting clinically meaningful change.

Combination approaches will also gain momentum. Pairing anti-VEGF with agents targeting angiopoietin-Tie2, complement, or inflammatory pathways offers the potential to stabilize microvascular disease more comprehensively. In practice, that means more complex study designs including multi-arm, adaptive platforms, and biomarker-enriched cohorts. These techniques are aimed at teasing apart which combinations provide substantial benefits without compounding safety risk.

For investigators, imaging and biomarker capabilities will become key differentiators. High-resolution OCT, OCT-A, and widefield imaging, paired with standardized grading by a central reading center (CRC), will be essential to support subtle morphologic endpoints. Sites that invest in this infrastructure now will be better positioned to participate in next-wave combinations and early-intervention trials.

IMPLICATIONS FOR SPONSORS AND CLINICAL SITES

For Sponsors, the future of retina clinical development will reward strategic focus and operational excellence. Trial design will continue to evolve toward more adaptive, data-rich designs. Sponsors should anticipate longer follow-up windows, more frequent multimodal imaging, and endpoints that capture both visual function and quality-of-life impact. Incorporating patient-reported outcomes that reflect real-world treatment burden (time in clinic, caregiver dependence, work productivity) will strengthen both regulatory and payer positioning.

For investigative sites, building a reputation for excellence for retina studies will hinge on three factors:

Consistent recruitment strategies for diverse patient populations

Meticulous imaging and data quality

Strong retention across multi-year studies

MOVING FORWARD

The retina field is entering a period of intense, opportunity-rich change. Sponsors who align their science, operations, and commercial thinking around durability, earlier intervention, and patient-centered outcomes will be best positioned to shape the future of retina development.

Leading Ophthalmology CRO

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries.

Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas.

Sponsors from emerging biotechs to global pharmaceutical companies have trusted Medpace for over 30 years to lead their ophthalmology development across a wide range of indications, including but not limited to Age-Related Macular Degeneration, Inherited Retinal Disease, Cataracts, Glaucoma, Cornea, and Diabetic Macular Edema.

Learn More

Contact our experts